Lenvatinib plus Pembrolizumab or Everolimus for Advanced Renal Cell Carcinoma
0
Authors
Robert Motzer
Robert Motzer•María Méndez-Vidal•Toni Choueiri
Published
February 13, 2021
Abstract
Lenvatinib in combination with pembrolizumab or everolimus has activity against advanced renal cell carcinoma. The efficacy of these regimens as compared with that of sunitinib is unclear.
